Innovative therapeutics

Investors

Financial Statements

NASDAQBMRN
All numbers in thousands USD
Period Ending
Sep 30, 2017
Jun 30, 2017
Mar 31, 2017
Dec 31, 2016
Total Revenue
334,148
317,448
303,745
300,091
Cost of Revenue
59,480
56,305
50,006
64,147
Gross Profit
274,668
261,143
253,739
235,944
Operating Expenses
Research Development
154,103
143,039
145,003
175,242
Selling General and Administrative
130,532
143,505
120,019
142,958
Non Recurring
--
--
--
--
Others
3,760
13,411
8,925
7,365
Total Operating Expenses
288,395
299,955
273,947
325,565
Operating Income or Loss
(13,727)
(38,812)
(20,208)
(89,621)
Income from Continuing Operations
Total Other Income/Expenses Net
14
(7,523)
(4,751)
4,261
Earnings Before Interest And Taxes
(9,737)
(43,352)
(21,887)
(82,434)
Interest Expense
10,884
2,194
2,419
9,732
Income Before Tax
(20,621)
(45,546)
(24,306)
(92,166)
Income Tax Expense
(8,094)
(8,713)
(8,016)
(13,455)
Minority Interest
--
--
--
--
Net Income From Continuing Ops
(12,527)
(36,833)
(16,290)
(78,711)
Non-recurring Events
Discontinued Operations
--
--
--
--
Extraordinary Items
--
--
--
--
Effect Of Accounting Changes
--
--
--
--
Other Items
0
0
0
0
Net Income
(12,527)
(36,833)
(16,290)
(78,711)
Preferred Stock And Other Adjustments
--
--
--
--
Net Income Applicable To Common Shares
(12,527)
(36,833)
(16,290)
(78,711)

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Brineura™
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information